Ladarixin - CAS 849776-05-2

Ladarixin (DF 2156A free base) is an orally active, non-competitive CXCR1/CXCR2 allosteric inhibitor that suppresses AKT, NF-κB, and angiogenesis, thereby slowing the progression of experimental human melanoma. It may be employed in research concerning COPD, asthma, and melanoma.

Akt, NF-κB, CXCR

Cytoskeletal Signaling, NF-κB, PI3K/Akt/mTOR signaling, GPCR/G Protein, Autophagy, Immunology/Inflammation

849776-05-2

0.9936

C11H12F3NO6S2

375.34

C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1

-20°C

Ice Packs

Small Compound